Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)

Colorectal Cancer Clinical Trial

Official title:

An Open-label, Dose-escalation, Phase 1 Study to Investigate the Safety and Tolerability of WM-A1-3389, in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05872867
• Other study ID #: WMA13389-101
• Secondary ID: MK-3475-E90KEYNO
• Status: Recruiting
• Phase: Phase 1
• Start date: March 14, 2024
• Est. completion date: February 22, 2026

Study information

• Verified date: October 2023
• Source: Wellmarker Bio
• Contact: Wellmarker BIO
• Phone: +82-2-6933-5667
• Email: selee[@]wmbio.co
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the present study is to determine the safety, tolerability, and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancer (NSCLC).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 54
• Est. completion date: February 22, 2026
• Est. primary completion date: February 22, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

[Stage 1: monotherapy]

1. Be =19 and <75 years of age

2. Participant with histologically and/or cytologically confirmed diagnosis of unresectable advanced or metastatic solid tumors that have been confirmed as progressed disease after standard of care or for which no further standard therapy is available due to intolerance or incompatibility

3. IGSF1 positive expression

4. Have measurable disease defined as at least one lesion based on Response Evaluation Criteria In Solid Tumors (RECIST) v1.1

5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

6. Have life expectancy = 12 weeks

7. Have adequate organ functions defined as the following laboratory test criteria at screening (During the screening phase, one re-test will be permitted):

1. Absolute neutrophil count (ANC) = 1,500/mm3

2. Platelet count = 100,000/mm3

3. Hemoglobin (Hb) = 9 g/dL

4. Total bilirubin = 1.5 X Institutional Upper Limit of Normal (IULN) (Not applicable to patients with Gilbert syndrome)

5. Serum creatinine = 1.5 X IULN

6. Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) = 2.5 X IULN (AST and ALT = 5 X IULN in patients with confirmed liver metastasis)

7. Prothrombin time (PT) = 1.5 X IULN *IULN: Institutional Upper Limit of Normal

8. Have provided archival tumor tissue sample obtained within 3 months prior to IP administration or newly obtained biopsy

9. Have agreed to undergo up to 2 tumor tissue biopsies after IP administration

10. Participant (or legally acceptable representative if applicable) provides written informed consent for the trial

[Stage 2: Combination therapy]

1. Be = 19 and < 75 years of age

2. Participant with histologically and/or cytologically confirmed diagnosis of unresectable advanced or metastatic NSCLC

1. Have been confirmed as progressive disease after standard of care or for which no further standard therapy is available due to intolerance or incompatibility

2. Have been confirmed as progressive disease during or after anti-cancer therapy including programmed cell death protein 1 (PD-1) inhibitors and programmed cell death-Ligand 1 (PD-L1) inhibitors

3. IGSF1 positive expression

4. PD-L1 low or negative expression (tumor proportion score [TPS] < 50%)

3. Have measurable disease defined as at least one lesion based on Response Evaluation Criteria In Solid Tumors (RECIST) v1.1

4. Have ECOG performance status score of 0 or 1

5. Have life expectancy = 12 weeks

6. Have adequate organ functions defined as the following laboratory test criteria at screening (During the screening period, one re-test will be permitted):

1. Absolute neutrophil count (ANC) = 1500/mm3

2. Platelet count = 100,000/mm3

3. Hemoglobin (Hb) = 9 g/dL

4. Total bilirubin = 1.5 X IULN (Not applicable to patients with Gilbert's syndrome)

5. Serum creatinine = 1.5 X IULN

6. Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) = 2.5 X IULN (AST and ALT = 5 X IULN in patients with confirmed liver metastasis)

7. Prothrombin time (PT) = 1.5 X IULN *IULN: Institutional Upper Limit of Normal

7. Have provided archival tumor sample obtained within 3 months prior to IP administration or newly obtained biopsy prior to IP administration

8. Have agreed to undergo up to 2 tumor tissue biopsies after IP administration

9. Participant (or legally acceptable representative if applicable) provides written infromed consent for the trial

Exclusion Criteria:

[Common]

1. Have experienced hypersensitivity to IP, any of its excipients or other monoclonal antibody

2. Have any of the following documented medical history or surgical/procedure history:

1. Other primary malignant tumor (subject may be enrolled if they have neither received any treatment nor experienced disease progression within 3 years) or hematologic malignancy

2. Major surgery within 4 weeks or minor surgery within 2 weeks prior to IP administration

3. Clinically significant arrhythmia, acute myocardial infarction, unstable angina pectoris, or New York Heart Association (NYHA) class ? or ? heart failure within 6 months prior to IP administration

4. Severe cerebrovascular disease within 6 months prior to IP administration

5. Pulmonary thrombosis, deep vein thrombosis, bronchial asthma, obstructive pulmonary disease, or other severe or life-threatening lung diseases (e.g., acute respiratory distress syndrome, lung failure) considered to be inappropriate for study participationt, within 6 months prior to IP administration

6. Pneumonia or interstitial lung disease requiring steroids

f. Infection requiring systemic antibiotics or antiviral agents, etc. or uncontorlled Grade = 3 active infectious diseases within 2 weeks prior to IP administration g. Risk factors of ileus or intestinal perforation (including but not limited to history of acute diverticulitis, intra-abdominal abscess, and abdominal carcinomatosis) h. Auto-immune diseases

3. Have any of the following diseases:

1. Central nervous system or brain metastasis that is uncontrolled or with clinically significant symptoms (except for patients who stopped systemic corticosteroids at least 4 weeks before IP administration and have been stable for at least 4 weeks)

2. Abnormal ECG regarded as clinically significant by the investigator

3. Uncontrolled hypertension (systolic blood pressure [SBP] > 160 mmHg or diastolic blood pressure [DBP] > 100 mmHg)

4. Active infection requiring treatment

5. Active hepatitis B or C virus infection

6. History of human immunodeficiency virus infection (HIV) infection

7. Symptomatic ascites or pleural effusion (except for patients who were treated and clinically stable)

8. Diseases that may affect the study results based on the judgement of the investigator

4. Have any of the following medication or treatment history:

1. Anticancer therapy (chemotherapy, hormonal therapy, targeted therapy, or radiotherapy) within 4 weeks prior to IP administration

2. Immunotherapy such as anti-PD-1, anti PD-L1, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), etc. within 4 weeks prior to IP administration

3. Treatment with live attenuated vaccine within 4 weeks prior to IP administration

4. Treatment with drugs classified as Immunosuppressants, immunomodulators, or immunocytokines within 1 week prior to IP administration (Immunosuppressants, topical corticosteroids, prednisolone 10 mg/day or = equivalent dose of systemic corticosteroids may be permitted for the treatment or prevention of AEs.)

5. Allogeneic bone marrow or solid organ transplantation

5. Pregnant women, lactating women or men/women of child-bearing potential who are unwilling to maintain abstinence or use adequate methods of contraception or do not consent to refrain from donation of sperm/ova for at least 6 months after the last IP administration

• Adequate methods of contraception

1. Oral or injectable hormonal therapy

2. Implantation of intrauterine device or intrauterine system

3. Surgical sterilization (vasectomy, tubal ligation, etc.)

6. Have received any other IP or implantation of investigational medical device within 4 weeks prior to IP administration in the present study

7. Patients who are considered ineligible or unable to participate in the study for other reasons based on the judgement of the investigator

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Carcinoma, Non-Small-Cell Lung
• Cholangiocarcinoma
• Colorectal Cancer
• Head and Neck Cancer
• Lung Cancer
• Lung Neoplasms
• Metastatic Solid Tumor
• Neoplasms
• Non Small Cell Lung Cancer
• Pancreatic Cancer

Intervention

Biological:
• WM-A1-3389
Anti-IGSF1 (Immunoglobulin superfamily member 1)
• Pembrolizumab
Anti-PD-1(Programmed cell death protein 1)

Locations

Country	Name	City	State
Korea, Republic of	Incheon St. Mary's Hospital	Incheon	Yeonsu-gu
Korea, Republic of	Seoul St. Mary's Hospital	Seoul	Seocho-gu

Sponsors (2)

Lead Sponsor	Collaborator
Wellmarker Bio	Merck Sharp & Dohme LLC

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Dose Limit Toxicities (DLT)		At the end of Cycle 1 (each cycle is 21 days)
Primary	Number of Participants Who Experienced an Adverse Event (AE)		Up to 6 Cycles (18 weeks)
Primary	Frequency of dose discontinuation and dose reduction due to ADRs		Up to 6 Cycles (18 weeks)
Secondary	Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumor (RECIST) v1.1		Screening, Subsequent Cycles (every 6 weeks), EOT (up to 18 weeks)
Secondary	Disease control rate (DCR) based on RECIST v1.1		Screening, Subsequent Cycles (every 6 weeks), EOT (up to 18 weeks)
Secondary	Disease control rate (DCR) based on Immune RECIST (iRECIST)		Screening, Subsequent Cycles (every 6 weeks), EOT (up to 18 weeks)
Secondary	Duration of response (DOR) based on RECIST v1.1		Screening, Subsequent Cycles (every 6 weeks), EOT (up to 18 weeks)
Secondary	Duration of response (DOR) based on iRECIST		Screening, Subsequent Cycles (every 6 weeks), EOT (up to 18 weeks)
Secondary	Overall survival (OS)		every 12 weeks after EOT (18 weeks)
Secondary	Progression free survival (PFS) based on RECIST v1.1		Screening, Subsequent Cycles (every 6 weeks), EOT (up to 18 weeks)
Secondary	Progression free survival (PFS) based on iRECIST		Screening, Subsequent Cycles (every 6 weeks), EOT (up to 18 weeks)
Secondary	Target tumor size	Maximum rate of change in the sum of the maximum length of the target lesion For target tumor size, the number of subjects, average, standard deviation, median, minimum, and maximum values by each dosing group are presented.	Screening, Subsequent Cycles (every 6 weeks), EOT (up to 18 weeks)
Secondary	Time to progression (TTP), time to response (TTR), time to failure (TTF), and other assessable efficacy endpoints		Screening, Subsequent Cycles (every 6 weeks), EOT (up to 18 weeks)
Secondary	Maximum Concentration (Cmax) of WM-A1-3389 or WM-A1-3389 with Pembrolizumab		Cycle 1, Cycle 2, Subsequent Cycles up to EOT (up to 18 weeks)
Secondary	Maximum Concentration at steady state (Cmax,ss) of WM-A1-3389 or WM-A1-3389 with Pembrolizumab		Cycle 1, Cycle 2, Subsequent Cycles up to EOT (up to 18 weeks)
Secondary	Minimum Concentration (Cmin) of WM-A1-3389 or WM-A1-3389 with Pembrolizumab		Cycle 1, Cycle 2, Subsequent Cycles up to EOT (up to 18 weeks)
Secondary	Minimum Concentration at steady state (Cmin,ss) of WM-A1-3389 or WM-A1-3389 with Pembrolizumab		Cycle 1, Cycle 2, Subsequent Cycles up to EOT (up to 18 weeks)
Secondary	Average Concentration at steady state (Cav,ss) of WM-A1-3389 or WM-A1-3389 with Pembrolizumab		Cycle 1, Cycle 2, Subsequent Cycles up to EOT (up to 18 weeks)
Secondary	Area under the curve (AUC) of WM-A1-3389 or WM-A1-3389 with Pembrolizumab		Cycle 1, Cycle 2, Subsequent Cycles up to EOT (up to 18 weeks)
Secondary	Area under the curve (AUC) from 0 to infinity of WM-A1-3389 or WM-A1-3389 with Pembrolizumab		Cycle 1, Cycle 2, Subsequent Cycles up to EOT (up to 18 weeks)
Secondary	Time to maximum concentration of WM-A1-3389 or WM-A1-3389 with Pembrolizumab		Cycle 1, Cycle 2, Subsequent Cycles up to EOT (up to 18 weeks)
Secondary	Time to maximum concentration at steady state of WM-A1-3389 or WM-A1-3389 with Pembrolizumab		Cycle 1, Cycle 2, Subsequent Cycles up to EOT (up to 18 weeks)
Secondary	Half life of WM-A1-3389 or WM-A1-3389 with Pembrolizumab		Cycle 1, Cycle 2, Subsequent Cycles up to EOT (up to 18 weeks)
Secondary	Peak trough fluctuation (PTF) of WM-A1-3389 or WM-A1-3389 with Pembrolizumab		Cycle 1, Cycle 2, Subsequent Cycles up to EOT (up to 18 weeks)
Secondary	Accumulation ratio (AR) of WM-A1-3389 or WM-A1-3389 with Pembrolizumab		Cycle 1, Cycle 2, Subsequent Cycles up to EOT (up to 18 weeks)
Secondary	Clearance rate (CL) of WM-A1-3389 or WM-A1-3389 with Pembrolizumab		Cycle 1, Cycle 2, Subsequent Cycles up to EOT (up to 18 weeks)
Secondary	Volume of distribution (Vz) of WM-A1-3389 or WM-A1-3389 with Pembrolizumab		Cycle 1, Cycle 2, Subsequent Cycles up to EOT (up to 18 weeks)
Secondary	Number of participants with anti-WM-A1-3389 antibodies (Stage 1 only)		Up to EOT (up to 18 weeks)